Home > Drugs A-Z > ZOSTAVAX

ZOSTAVAX (Merck Sharp & Dohme Corp.)

Available Formats

Dosage Form Package Information Links
INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION 10 VIAL, SINGLE-DOSE in 1 CARTON (0006-4963-41) > .65 mL in 1 VIAL, SINGLE-DOSE (0006-4963-01) Label Information
INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION 1 VIAL, SINGLE-DOSE in 1 CARTON (0006-4963-00) > .65 mL in 1 VIAL, SINGLE-DOSE (0006-4963-01) Label Information

Complete ZOSTAVAX Information

  • HIGHLIGHTS OF PRESCRIBING INFORMATION
    These highlights do not include all the information needed to use ZOSTAVAX safely and effectively. See full prescribing information for ZOSTAVAX.

    ZOSTAVAX® (Zoster Vaccine Live)
    Suspension for subcutaneous injection
    Initial U.S. Approval: 2006

    RECENT MAJOR CHANGES

    Contraindications, Immunosuppression (4.2) 09/2017

    INDICATIONS AND USAGE

    ZOSTAVAX is a live attenuated virus vaccine indicated for prevention of herpes zoster (shingles) in individuals 50 years of age and older. (1)


    Limitations of Use of ZOSTAVAX:

    • ZOSTAVAX is not indicated for the treatment of zoster or postherpetic neuralgia (PHN) (1)
    • ZOSTAVAX is not indicated for prevention of primary varicella infection (Chickenpox) (1)

    DOSAGE AND ADMINISTRATION

    Single 0.65 mL subcutaneous injection (2.1)

    DOSAGE FORMS AND STRENGTHS

    Single dose vials with not less than 19,400 plaque-forming units [PFU] per 0.65 mL dose when reconstituted to a suspension. (2.1, 3, 16)

    CONTRAINDICATIONS

    • History of anaphylactic/anaphylactoid reaction to gelatin, neomycin, or any other component of the vaccine. (4.1)
    • Immunosuppression or Immunodeficiency. (4.2)
    • Pregnancy. (4.3, 8.1)

    WARNINGS AND PRECAUTIONS

    • Hypersensitivity reactions including anaphylaxis have occurred with ZOSTAVAX (5.1)
    • Transmission of vaccine virus may occur between vaccinees and susceptible contacts (5.2)
    • Deferral should be considered in acute illness (for example, in the presence of fever) or in patients with active untreated tuberculosis (5.3)
    • Avoid pregnancy for 3 months following vaccination with ZOSTAVAX (8.1)

    ADVERSE REACTIONS

    The most frequent adverse reactions, reported in ≥1% of subjects vaccinated with ZOSTAVAX, were headache and injection-site reactions. (6


    To report SUSPECTED ADVERSE REACTIONS, contact Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., at 1-877-888-4231 or VAERS at 1-800-822-7967 or www.vaers.hhs.gov.

    DRUG INTERACTIONS

    In a randomized clinical study, a reduced immune response to ZOSTAVAX as measured by gpELISA was observed in individuals who received concurrent administration of PNEUMOVAX® 23 and ZOSTAVAX compared with individuals who received these vaccines 4 weeks apart. Consider administration of the two vaccines separated by at least 4 weeks. (7.1, 14.3)

    USE IN SPECIFIC POPULATIONS

    Pregnancy: Do not administer ZOSTAVAX to females who are pregnant. Pregnancy should be avoided for 3 months following vaccination with ZOSTAVAX. (4.3, 8.1, 17)

    See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.

    Revised: 9/2017


  • FULL PRESCRIBING INFORMATION: CONTENTS*
  • 1 INDICATIONS AND USAGE

    ZOSTAVAX® is a live attenuated virus vaccine indicated for prevention of herpes zoster (shingles) in individuals 50 years of age and older.

    Limitations of Use of ZOSTAVAX:

    • ZOSTAVAX is not indicated for the treatment of zoster or postherpetic neuralgia (PHN).
    • ZOSTAVAX is not indicated for prevention of primary varicella infection (Chickenpox).

  • 2 DOSAGE AND ADMINISTRATION

    Subcutaneous administration only. Do not inject intravascularly or intramuscularly.

    2.1 Recommended Dose and Schedule

    Administer ZOSTAVAX as a single 0.65-mL dose subcutaneously in the deltoid region of the upper arm.

    2.2 Preparation for Administration

    Use only sterile syringes free of preservatives, antiseptics, and detergents for each injection and/or reconstitution of ZOSTAVAX. Preservatives, antiseptics and detergents may inactivate the vaccine virus.

    ZOSTAVAX is stored frozen and should be reconstituted immediately upon removal from the freezer.

    When reconstituted, ZOSTAVAX is a semi-hazy to translucent, off-white to pale yellow liquid.

    Reconstitution:

    • Use only the diluent supplied.
    • Withdraw the entire contents of the diluent into a syringe.
    • To avoid excessive foaming, slowly inject all of the diluent in the syringe into the vial of lyophilized vaccine and gently agitate to mix thoroughly.
    • Withdraw the entire contents of reconstituted vaccine into a syringe and inject the total volume subcutaneously.
    • ADMINISTER IMMEDIATELY AFTER RECONSTITUTION to minimize loss of potency. Discard reconstituted vaccine if not used within 30 minutes. Do not freeze reconstituted vaccine.

  • 3 DOSAGE FORMS AND STRENGTHS

    ZOSTAVAX is a lyophilized preparation of live, attenuated varicella-zoster virus (Oka/Merck) to be reconstituted with sterile diluent to give a single dose suspension with a minimum of 19,400 PFU (plaque forming units) when stored at room temperature for up to 30 minutes.


  • 4 CONTRAINDICATIONS

    4.1 Hypersensitivity

    Do not administer ZOSTAVAX to individuals with a history of anaphylactic/anaphylactoid reaction to gelatin, neomycin or any other component of the vaccine. Neomycin allergy manifested as contact dermatitis is not a contraindication to receiving this vaccine. {1}

    4.2 Immunosuppression

    ZOSTAVAX is a live, attenuated varicella-zoster vaccine and administration to individuals who are immunosuppressed or immunodeficient may result in disseminated varicella-zoster virus disease, including fatal outcomes. Do not administer ZOSTAVAX to immunosuppressed or immunodeficient individuals including those with a history of primary or acquired immunodeficiency states, leukemia, lymphoma or other malignant neoplasms affecting the bone marrow or lymphatic system, AIDS or other clinical manifestations of infection with human immunodeficiency viruses, and those on immunosuppressive therapy.

    4.3 Pregnancy

    Do not administer ZOSTAVAX to pregnant women. Naturally occurring varicella-zoster virus (VZV) infection is known to sometimes cause fetal harm. Pregnancy should be avoided for 3 months following administration of ZOSTAVAX [see Use in Specific Populations (8.1) and Patient Counseling Information (17)].


  • 5 WARNINGS AND PRECAUTIONS

    5.1 Hypersensitivity Reactions

    Serious adverse reactions, including anaphylaxis, have occurred with ZOSTAVAX. Adequate treatment provisions, including epinephrine injection (1:1,000), should be available for immediate use should an anaphylactic/anaphylactoid reaction occur.

    5.2 Transmission of Vaccine Virus

    Transmission of vaccine virus may occur between vaccinees and susceptible contacts.

    5.3 Concurrent Illness

    Deferral should be considered in acute illness (for example, in the presence of fever) or in patients with active untreated tuberculosis.

    5.4 Limitations of Vaccine Effectiveness

    Vaccination with ZOSTAVAX does not result in protection of all vaccine recipients.

    The duration of protection beyond 4 years after vaccination with ZOSTAVAX is unknown. The need for revaccination has not been defined.


  • 6 ADVERSE REACTIONS

    The most frequent adverse reactions, reported in ≥1% of subjects vaccinated with ZOSTAVAX, were headache and injection-site reactions.

    6.1 Clinical Trials Experience

    Because clinical trials are conducted under widely varying conditions, rates of adverse reactions observed in the clinical trials of a vaccine cannot be directly compared to rates in the clinical trials of another vaccine and may not reflect the rates observed in practice.

    ZOSTAVAX Efficacy and Safety Trial (ZEST) in Subjects 50 to 59 Years of Age

    In the ZEST study, subjects received a single dose of either ZOSTAVAX (N=11,184) or placebo (N=11,212). The racial distribution across both vaccination groups was similar: White (94.4%); Black (4.2%); Hispanic (3.3%) and Other (1.4%) in both vaccination groups. The gender distribution was 38% male and 62% female in both vaccination groups. The age distribution of subjects enrolled, 50 to 59 years, was similar in both vaccination groups. All subjects received a vaccination report card (VRC) to record adverse events occurring from Days 1 to 42 postvaccination.

    In the ZEST study, serious adverse events occurred at a similar rate in subjects vaccinated with ZOSTAVAX (0.6%) or placebo (0.5%) from Days 1 to 42 postvaccination.

    In the ZEST study, all subjects were monitored for adverse reactions. An anaphylactic reaction was reported for one subject vaccinated with ZOSTAVAX.

    Most Common Adverse Reactions and Experiences in the ZEST Study

    The overall incidence of vaccine-related injection-site adverse reactions within 5 days postvaccination was greater for subjects vaccinated with ZOSTAVAX as compared to subjects who received placebo (63.6% for ZOSTAVAX and 14.0% for placebo). Injection-site adverse reactions occurring at an incidence ≥1% within 5 days postvaccination are shown in Table 1.

    Table 1: Injection-Site Adverse Reactions Reported in ≥1% of Adults Who Received ZOSTAVAX or Placebo Within 5 Days Postvaccination in the ZOSTAVAX Efficacy and Safety Trial
    *
    • Solicited on the Vaccination Report Card

    Injection-Site

    Adverse Reaction

    ZOSTAVAX

    (N = 11094)

    %

    Placebo

    (N = 11116)

    %

    Solicited*

        Pain

        Erythema

        Swelling


    53.9

    48.1

    40.4


    9.0

    4.3

    2.8

    Unsolicited

        Pruritus

        Warmth

        Hematoma

        Induration


    11.3

    3.7

    1.6

    1.1


    0.7

    0.2

    1.6

    0.0

    Systemic adverse reactions and experiences reported during Days 1-42 at an incidence of ≥1% in either vaccination group were headache (ZOSTAVAX 9.4%, placebo 8.2%) and pain in the extremity (ZOSTAVAX 1.3%, placebo 0.8%), respectively.

    The overall incidence of systemic adverse experiences reported during Days 1-42 was higher for ZOSTAVAX (35.4%) than for placebo (33.5%).

    Shingles Prevention Study (SPS) in Subjects 60 Years of Age and Older

    In the SPS, the largest clinical trial of ZOSTAVAX, subjects received a single dose of either ZOSTAVAX (n=19,270) or placebo (n=19,276). The racial distribution across both vaccination groups was similar: White (95%); Black (2.0%); Hispanic (1.0%) and Other (1.0%) in both vaccination groups. The gender distribution was 59% male and 41% female in both vaccination groups. The age distribution of subjects enrolled, 59-99 years, was similar in both vaccination groups.

    The Adverse Event Monitoring Substudy of the SPS, designed to provide detailed data on the safety profile of the zoster vaccine (n=3,345 received ZOSTAVAX and n=3,271 received placebo) used vaccination report cards (VRC) to record adverse events occurring from Days 0 to 42 postvaccination (97% of subjects completed VRC in both vaccination groups). In addition, monthly surveillance for hospitalization was conducted through the end of the study, 2 to 5 years postvaccination.

    The remainder of subjects in the SPS (n=15,925 received ZOSTAVAX and n=16,005 received placebo) were actively followed for safety outcomes through Day 42 postvaccination and passively followed for safety after Day 42.

    Serious Adverse Events Occurring 0-42 Days Postvaccination

    In the overall SPS study population, serious adverse events occurred at a similar rate (1.4%) in subjects vaccinated with ZOSTAVAX or placebo.

    In the AE Monitoring Substudy, the rate of SAEs was increased in the group of subjects who received ZOSTAVAX as compared to the group of subjects who received placebo (Table 2).

    Table 2: Number of Subjects with ≥1 Serious Adverse Events (0-42 Days Postvaccination) in the Shingles Prevention Study
    Cohort ZOSTAVAX
    n/N
    %
    Placebo
    n/N
    %
    Relative Risk
    (95% CI)
    N=number of subjects in cohort with safety follow-up
    n=number of subjects reporting an SAE 0-42 Days postvaccination
    Overall Study Cohort
    (60 years of age and older)
    255/18671
    1.4%
    254/18717
    1.4%
    1.01
    (0.85, 1.20)
      60-69 years old 113/10100
    1.1%
    101/10095
    1.0%
    1.12
    (0.86, 1.46)
      70-79 years old 115/7351
    1.6%
    132/7333
    1.8%
    0.87
    (0.68, 1.11)
      â‰¥80 years old 27/1220
    2.2%
    21/1289
    1.6%
    1.36
    (0.78, 2.37)
    AE Monitoring Substudy Cohort
    (60 years of age and older)
    64/3326
    1.9%
    41/3249
    1.3%
    1.53
    (1.04, 2.25)
      60-69 years old 22/1726
    1.3%
    18/1709
    1.1%
    1.21
    (0.66, 2.23)
      70-79 years old 31/1383
    2.2%
    19/1367
    1.4%
    1.61
    (0.92, 2.82)
      â‰¥80 years old 11/217
    5.1%
    4/173
    2.3%
    2.19
    (0.75, 6.45)

    Among reported serious adverse events in the SPS (Days 0 to 42 postvaccination), serious cardiovascular events occurred more frequently in subjects who received ZOSTAVAX (20 [0.6%]) than in subjects who received placebo (12 [0.4%]) in the AE Monitoring Substudy. The frequencies of serious cardiovascular events were similar in subjects who received ZOSTAVAX (81 [0.4%]) and in subjects who received placebo (72 [0.4%]) in the entire study cohort (Days 0 to 42 postvaccination).

    Serious Adverse Events Occurring Over the Entire Course of the Study

    Rates of hospitalization were similar among subjects who received ZOSTAVAX and subjects who received placebo in the AE Monitoring Substudy, throughout the entire study.

    Fifty-one individuals (1.5%) receiving ZOSTAVAX were reported to have congestive heart failure (CHF) or pulmonary edema compared to 39 individuals (1.2%) receiving placebo in the AE Monitoring Substudy; 58 individuals (0.3%) receiving ZOSTAVAX were reported to have congestive heart failure (CHF) or pulmonary edema compared to 45 (0.2%) individuals receiving placebo in the overall study.

    In the SPS, all subjects were monitored for vaccine-related SAEs. Investigator-determined, vaccine-related serious adverse experiences were reported for 2 subjects vaccinated with ZOSTAVAX (asthma exacerbation and polymyalgia rheumatica) and 3 subjects who received placebo (Goodpasture's syndrome, anaphylactic reaction, and polymyalgia rheumatica).

    Deaths

    The incidence of death was similar in the groups receiving ZOSTAVAX or placebo during the Days 0-42 postvaccination period; 14 deaths occurred in the group of subjects who received ZOSTAVAX and 16 deaths occurred in the group of subjects who received placebo. The most common reported cause of death was cardiovascular disease (10 in the group of subjects who received ZOSTAVAX, 8 in the group of subjects who received placebo). The overall incidence of death occurring at any time during the study was similar between vaccination groups: 793 deaths (4.1%) occurred in subjects who received ZOSTAVAX and 795 deaths (4.1%) in subjects who received placebo.

    Most Common Adverse Reactions and Experiences in the AE Monitoring Substudy of the SPS

    Injection-site adverse reactions reported at an incidence ≥1% are shown in Table 3. Most of these adverse reactions were reported as mild in intensity. The overall incidence of vaccine-related injection-site adverse reactions was significantly greater for subjects vaccinated with ZOSTAVAX versus subjects who received placebo (48% for ZOSTAVAX and 17% for placebo).

    Table 3: Injection-Site Adverse Reactions* in ≥1% of Adults Who Received ZOSTAVAX or Placebo Within 5 Days Postvaccination from the AE Monitoring Substudy of the Shingles Prevention Study
    Adverse Reaction

    ZOSTAVAX

    (N = 3345)

    %

    Placebo

    (N = 3271)

    %
    *
    • Patients instructed to report adverse experiences on a Vaccination Report Card
    †
    • Solicited on the Vaccination Report Card

    Solicited†

    Erythema

    Pain/Tenderness

    Swelling


    35.6

    34.3

    26.1


    6.9

    8.3

    4.5

    Unsolicited

    Hematoma

    Pruritus

    Warmth


    1.6

    6.9

    1.6


    1.4

    1.0

    0.3

    Headache was the only systemic adverse reaction reported on the vaccine report card between Days 0-42 by ≥1% of subjects in the AE Monitoring Substudy in either vaccination group (ZOSTAVAX 1.4%, placebo 0.8%).

    The numbers of subjects with elevated temperature (≥38.3°C [≥101.0°F]) within 42 days postvaccination were similar in the ZOSTAVAX and the placebo vaccination groups [27 (0.8%) vs. 27 (0.9%), respectively].

    The following adverse experiences in the AE Monitoring Substudy of the SPS (Days 0 to 42 postvaccination) were reported at an incidence ≥1% and greater in subjects who received ZOSTAVAX than in subjects who received placebo, respectively: respiratory infection (65 [1.9%] vs. 55 [1.7%]), fever (59 [1.8%] vs. 53 [1.6%]), flu syndrome (57 [1.7%] vs. 52 [1.6%]), diarrhea (51 [1.5%] vs. 41 [1.3%]), rhinitis (46 [1.4%] vs. 36 [1.1%]), skin disorder (35 [1.1%] vs. 31 [1.0%]), respiratory disorder (35 [1.1%] vs. 27 [0.8%]), asthenia (32 [1.0%] vs. 14 [0.4%]).

    6.2 VZV Rashes Following Vaccination

    Within the 42-day postvaccination reporting period in the ZEST, noninjection-site zoster-like rashes were reported by 34 subjects (19 for ZOSTAVAX and 15 for placebo). Of 24 specimens that were adequate for Polymerase Chain Reaction (PCR) testing, wild-type VZV was detected in 10 (3 for ZOSTAVAX, 7 for placebo) of these specimens. The Oka/Merck strain of VZV was not detected from any of these specimens. Of reported varicella-like rashes (n=124, 69 for ZOSTAVAX and 55 for placebo), 23 had specimens that were available and adequate for PCR testing. VZV was detected in one of these specimens in the ZOSTAVAX group; however, the virus strain (wild-type or Oka/Merck strain) could not be determined.

    Within the 42-day postvaccination reporting period in the SPS, noninjection-site zoster-like rashes were reported by 53 subjects (17 for ZOSTAVAX and 36 for placebo). Of 41 specimens that were adequate for Polymerase Chain Reaction (PCR) testing, wild-type VZV was detected in 25 (5 for ZOSTAVAX, 20 for placebo) of these specimens. The Oka/Merck strain of VZV was not detected from any of these specimens.

    Of reported varicella-like rashes (n=59), 10 had specimens that were available and adequate for PCR testing. VZV was not detected in any of these specimens.

    In clinical trials in support of the initial licensure of the frozen formulation of ZOSTAVAX, the reported rates of noninjection-site zoster-like and varicella-like rashes within 42 days postvaccination were also low in both zoster vaccine and placebo recipients. Of 17 reported varicella-like rashes and non-injection site zoster-like rashes, 10 specimens were available and adequate for PCR testing, and 2 subjects had varicella (onset Day 8 and 17) confirmed to be Oka/Merck strain.

    6.3 Post-Marketing Experience

    The following additional adverse reactions have been identified during post-marketing use of ZOSTAVAX. Because these reactions are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency or establish a causal relationship to the vaccine.

    Gastrointestinal disorders: nausea

    Infections and infestations: herpes zoster (vaccine strain)

    Skin and subcutaneous tissue disorders: rash

    Musculoskeletal and connective tissue disorders: arthralgia; myalgia

    General disorders and administration site conditions: injection-site rash; pyrexia; injection-site urticaria; transient injection-site lymphadenopathy

    Immune system disorders: hypersensitivity reactions including anaphylactic reactions

    Eye Disorders: necrotizing retinitis (patients on immunosuppressive therapy)

    Reporting Adverse Events

    The U.S. Department of Health and Human Services has established a Vaccine Adverse Event Reporting System (VAERS) to accept all reports of suspected adverse events after the administration of any vaccine. For information or a copy of the vaccine reporting form, call the VAERS toll-free number at 1-800-822-7967 or report online to www.vaers.hhs.gov. {2}


  • 7 DRUG INTERACTIONS

    7.1 Concomitant Administration with Other Vaccines

    In a randomized clinical study, a reduced immune response to ZOSTAVAX as measured by gpELISA was observed in individuals who received concurrent administration of PNEUMOVAX® 23 and ZOSTAVAX compared with individuals who received these vaccines 4 weeks apart. Consider administration of the two vaccines separated by at least 4 weeks [see Clinical Studies (14.3)].

    For concomitant administration of ZOSTAVAX with inactivated influenza vaccine [see Clinical Studies (14.3)].

    7.2 Antiviral Medications

    Concurrent administration of ZOSTAVAX and antiviral medications known to be effective against VZV has not been evaluated.


  • 8 USE IN SPECIFIC POPULATIONS

    8.1 Pregnancy

    Risk Summary

    ZOSTAVAX is contraindicated for use in pregnant women because the vaccine contains live, attenuated varicella-zoster virus, and it is known that wild-type varicella-zoster virus, if acquired during pregnancy, can cause congenital varicella syndrome [see Contraindications (4.3) and Patient Counseling Information (17)].

    Available data on inadvertent administration of ZOSTAVAX to pregnant women are insufficient to inform vaccine-associated risks in pregnancy.

    All pregnancies have a risk of birth defect, loss, or other adverse outcomes. In the US general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

    8.2 Lactation

    Risk Summary

    It is not known whether varicella-zoster vaccine virus is excreted in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for ZOSTAVAX, and any potential adverse effects on the breastfed child from ZOSTAVAX or from the underlying maternal condition. For preventive vaccines, the underlying maternal condition is susceptibility to disease prevented by the vaccine.

    8.4 Pediatric Use

    ZOSTAVAX is not indicated for prevention of primary varicella infection (Chickenpox) and should not be used in children and adolescents.

    8.5 Geriatric Use

    The median age of subjects enrolled in the largest (N=38,546) clinical study of ZOSTAVAX was 69 years (range 59-99 years). Of the 19,270 subjects who received ZOSTAVAX, 10,378 were 60-69 years of age, 7,629 were 70-79 years of age, and 1,263 were 80 years of age or older.


  • 11 DESCRIPTION

    ZOSTAVAX is a lyophilized preparation of the Oka/Merck strain of live, attenuated varicella-zoster virus (VZV). ZOSTAVAX, when reconstituted as directed, is a sterile suspension for subcutaneous administration. Each 0.65-mL dose contains a minimum of 19,400 PFU (plaque-forming units) of Oka/Merck strain of VZV when reconstituted and stored at room temperature for up to 30 minutes.

    Each dose contains 31.16 mg of sucrose, 15.58 mg of hydrolyzed porcine gelatin, 3.99 mg of sodium chloride, 0.62 mg of monosodium L-glutamate, 0.57 mg of sodium phosphate dibasic, 0.10 mg of potassium phosphate monobasic, 0.10 mg of potassium chloride; residual components of MRC-5 cells including DNA and protein; and trace quantities of neomycin and bovine calf serum. The product contains no preservatives.


  • 12 CLINICAL PHARMACOLOGY

    12.1 Mechanism of Action

    The risk of developing zoster appears to be related to a decline in VZV-specific immunity. ZOSTAVAX was shown to boost VZV-specific immunity, which is thought to be the mechanism by which it protects against zoster and its complications. [See Clinical Studies (14).]

    Herpes zoster (HZ), commonly known as shingles or zoster, is a manifestation of the reactivation of varicella zoster virus (VZV), which, as a primary infection, produces chickenpox (varicella). Following initial infection, the virus remains latent in the dorsal root or cranial sensory ganglia until it reactivates, producing zoster. Zoster is characterized by a unilateral, painful, vesicular cutaneous eruption with a dermatomal distribution.

    Pain associated with zoster may occur during the prodrome, the acute eruptive phase, and the postherpetic phase of the infection. Pain occurring in the postherpetic phase of infection is commonly referred to as postherpetic neuralgia (PHN).

    Serious complications, such as PHN, scarring, bacterial superinfection, allodynia, cranial and motor neuron palsies, pneumonia, encephalitis, visual impairment, hearing loss, and death can occur as the result of zoster.


  • 13 NONCLINICAL TOXICOLOGY

    13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

    ZOSTAVAX has not been evaluated for its carcinogenic or mutagenic potential, or its potential to impair fertility.


  • 14 CLINICAL STUDIES

    In two large clinical trials (ZEST and SPS), ZOSTAVAX significantly reduced the risk of developing zoster when compared with placebo (see Table 4 and Table 5).

    14.1 ZOSTAVAX Efficacy and Safety Trial (ZEST) in Subjects 50 to 59 Years of Age

    Efficacy of ZOSTAVAX was evaluated in the ZOSTAVAX Efficacy and Safety Trial (ZEST), a placebo-controlled, double-blind clinical trial in which 22,439 subjects 50 to 59 years of age were randomized to receive a single dose of either ZOSTAVAX (n=11,211) or placebo (n=11,228). Subjects were followed for the development of zoster for a median of 1.3 years (range 0 to 2 years). Confirmed zoster cases were determined by Polymerase Chain Reaction (PCR) [86%] or, in the absence of virus detection, by a Clinical Evaluation Committee [14%]. The primary efficacy analysis included all subjects randomized in the study (intent-to-treat [ITT] analysis).

    Compared with placebo, ZOSTAVAX significantly reduced the risk of developing zoster by 69.8% (95% CI [54.1, 80.6%]) in subjects 50 to 59 years of age (Table 4).

    Table 4: Efficacy of ZOSTAVAX on HZ Incidence Compared with Placebo in the ZOSTAVAX Efficacy and Safety Trial*
    *
    • The analysis was performed on the intent-to-treat (ITT) population that included all subjects randomized in the ZEST study.
    ZOSTAVAX Placebo
    Age group (yrs.) # subjects # HZ cases Incidence rate of HZ per 1000 person-yrs. # subjects # HZ cases Incidence rate of HZ per 1000 person-yrs. Vaccine Efficacy
    (95% CI)
    50-59 11211 30 1.994 11228 99 6.596 69.8% (54.1%, 80.6%)

    Immune responses to vaccination were evaluated in a random 10% subcohort (n=1,136 for ZOSTAVAX and n=1,133 for placebo) of the subjects enrolled in the ZEST study. VZV antibody levels (Geometric Mean Titers, GMT), as measured by glycoprotein enzyme-linked immunosorbent assay (gpELISA) 6 weeks postvaccination, were increased 2.3-fold [95% CI (2.2, 2.4)] in the group of subjects who received ZOSTAVAX compared to subjects who received placebo; the specific antibody level that correlates with protection from zoster has not been established.

    14.2 Shingles Prevention Study (SPS) in Subjects 60 Years of Age and Older

    Efficacy of ZOSTAVAX was evaluated in the Shingles Prevention Study (SPS), a placebo-controlled, double-blind clinical trial in which 38,546 subjects 60 years of age or older were randomized to receive a single dose of either ZOSTAVAX (n=19,270) or placebo (n=19,276). Subjects were followed for the development of zoster for a median of 3.1 years (range 31 days to 4.90 years). The study excluded people who were immunocompromised or using corticosteroids on a regular basis, anyone with a previous history of HZ, and those with conditions that might interfere with study evaluations, including people with cognitive impairment, severe hearing loss, those who were non-ambulatory, and those whose survival was not considered to be at least 5 years. Randomization was stratified by age, 60-69 and ≥70 years of age. Suspected zoster cases were confirmed by Polymerase Chain Reaction (PCR) [93%], viral culture [1%], or in the absence of virus detection, as determined by a Clinical Evaluation Committee [6%]. Individuals in both vaccination groups who developed zoster were given famciclovir, and, as necessary, pain medications. The primary efficacy analysis included all subjects randomized in the study who were followed for at least 30 days postvaccination and did not develop an evaluable case of HZ within the first 30 days postvaccination (Modified Intent-To-Treat [MITT] analysis).

    ZOSTAVAX significantly reduced the risk of developing zoster when compared with placebo (Table 5). In the SPS, vaccine efficacy for the prevention of HZ was highest for those subjects 60-69 years of age and declined with increasing age.

    Table 5: Efficacy of ZOSTAVAX on HZ Incidence Compared with Placebo in the Shingles Prevention Study*
    Age group† (yrs.) ZOSTAVAX Placebo

    Vaccine Efficacy

    (95% CI)

    # subjects # HZ cases Incidence rate of HZ per 1000 person-yrs. # subjects # HZ cases Incidence rate of HZ per 1000 person-yrs.
    *
    • The analysis was performed on the Modified Intent-To-Treat (MITT) population that included all subjects randomized in the study who were followed for at least 30 days postvaccination and did not develop an evaluable case of HZ within the first 30 days postvaccination.
    †
    • Age strata at randomization were 60-69 and ≥70 years of age.
    Overall 19254 315 5.4 19247 642 11.1 51% (44%, 58%)
    60-69 10370 122 3.9 10356 334 10.8 64% (56%, 71%)
    70-79 7621 156 6.7 7559 261 11.4 41% (28%, 52%)
    ≥80 1263 37 9.9 1332 47 12.2 18% (-29%, 48%)

    Forty-five subjects were excluded from the MITT analysis (16 in the group of subjects who received ZOSTAVAX and 29 in the group of subjects who received placebo), including 24 subjects with evaluable HZ cases that occurred in the first 30 days postvaccination (6 evaluable HZ cases in the group of subjects who received ZOSTAVAX and 18 evaluable HZ cases in the group of subjects who received placebo).

    Suspected HZ cases were followed prospectively for the development of HZ-related complications. Table 6 compares the rates of PHN defined as HZ-associated pain (rated as 3 or greater on a 10-point scale by the study subject and occurring or persisting at least 90 days) following the onset of rash in evaluable cases of HZ.

    Table 6: Postherpetic Neuralgia (PHN)* in the Shingles Prevention Study†

    Age group (yrs.)‡
    ZOSTAVAX Placebo
    Vaccine efficacy against PHN in subjects who develop HZ postvaccination
    (95% CI)
    # subjects # HZ cases # PHN cases Incidence rate of PHN per 1,000 person-yrs. % HZ cases with PHN # subjects # HZ cases # PHN cases Incidence rate of PHN per 1,000 person-yrs. % HZ cases with PHN
    *
    • PHN was defined as HZ-associated pain rated as ≥3 (on a 0-10 scale), persisting or appearing more than 90 days after onset of HZ rash using Zoster Brief Pain Inventory (ZBPI). { 5}
    †
    • The table is based on the Modified Intent-To-Treat (MITT) population that included all subjects randomized in the study who were followed for at least 30 days postvaccination and did not develop an evaluable case of HZ within the first 30 days postvaccination.
    ‡
    • Age strata at randomization were 60-69 and ≥70 years of age.
    §
    • Age-adjusted estimate based on the age strata (60-69 and ≥70 years of age) at randomization.
    Overall 19254 315 27 0.5 8.6% 19247 642 80 1.4 12.5% 39%§
    (7%, 59%)
    60-69 10370 122 8 0.3 6.6% 10356 334 23 0.7 6.9% 5%
    (-107%, 56%)
    70-79 7621 156 12 0.5 7.7% 7559 261 45 2.0 17.2% 55%
    (18%, 76%)
    ≥80 1263 37 7 1.9 18.9% 1332 47 12 3.1 25.5% 26%
    (-69%, 68%)

    The median duration of clinically significant pain (defined as ≥3 on a 0-10 point scale) among HZ cases in the group of subjects who received ZOSTAVAX as compared to the group of subjects who received placebo was 20 days vs. 22 days based on the confirmed HZ cases.

    Overall, the benefit of ZOSTAVAX in the prevention of PHN can be primarily attributed to the effect of the vaccine on the prevention of herpes zoster. Vaccination with ZOSTAVAX in the SPS reduced the incidence of PHN in individuals 70 years of age and older who developed zoster postvaccination. Other prespecified zoster-related complications were reported less frequently in subjects who received ZOSTAVAX compared to subjects who received placebo. Among HZ cases, zoster-related complications were reported at similar rates in both vaccination groups (Table 7).

    Table 7: Specific complications* of zoster among HZ cases in the Shingles Prevention Study
    Complication ZOSTAVAX
    (N = 19270)
    Placebo
    (N = 19276)
    (n = 321) % Among
    Zoster Cases
    (n = 659) % Among
    Zoster Cases
    N=number of subjects randomized
    n=number of zoster cases, including those cases occurring within 30 days postvaccination, with these data available
    *
    • Complications reported at a frequency of ≥1% in at least one vaccination group among subjects with zoster
    Allodynia 135 42.1 310 47.0
    Bacterial Superinfection 3 0.9 7 1.1
    Dissemination 5 1.6 11 1.7
    Impaired Vision 2 0.6 9 1.4
    Ophthalmic Zoster 35 10.9 69 10.5
    Peripheral Nerve Palsies (motor) 5 1.6 12 1.8
    Ptosis 2 0.6 9 1.4
    Scarring 24 7.5 57 8.6
    Sensory Loss 7 2.2 12 1.8

    Visceral complications reported by fewer than 1% of subjects with zoster included 3 cases of pneumonitis and 1 case of hepatitis in the placebo group, and 1 case of meningoencephalitis in the vaccine group.

    Immune responses to vaccination were evaluated in a subset of subjects enrolled in the Shingles Prevention Study (N=1,395). VZV antibody levels (Geometric Mean Titers, GMT), as measured by glycoprotein enzyme-linked immunosorbent assay (gpELISA) 6 weeks postvaccination, were increased 1.7-fold (95% CI: [1.6 to 1.8]) in the group of subjects who received ZOSTAVAX compared to subjects who received placebo; the specific antibody level that correlates with protection from zoster has not been established.

    14.3 Concomitant Use Studies

    In a double-blind, controlled substudy, 374 adults in the US, 60 years of age and older (median age = 66 years), were randomized to receive trivalent inactivated influenza vaccine (TIV) and ZOSTAVAX concurrently (N=188), or TIV alone followed 4 weeks later by ZOSTAVAX alone (N=186). The antibody responses to both vaccines at 4 weeks postvaccination were similar in both groups.

    In another double-blind, controlled study, 882 adults in the US, 50 years of age and older (median age = 60 years), were randomized to receive quadrivalent inactivated influenza vaccine and ZOSTAVAX concurrently (N=440), or quadrivalent inactivated influenza vaccine alone followed 4 weeks later by ZOSTAVAX alone (N=442). The antibody responses to both vaccines at 4 weeks postvaccination were similar in both groups.

    In a double-blind, controlled clinical trial, 473 adults, 60 years of age or older, were randomized to receive ZOSTAVAX and PNEUMOVAX 23 concomitantly (N=237), or PNEUMOVAX 23 alone followed 4 weeks later by ZOSTAVAX alone (N=236). At 4 weeks postvaccination, the VZV antibody levels following concomitant use were significantly lower than the VZV antibody levels following nonconcomitant administration (GMTs of 338 vs. 484 gpELISA units/mL, respectively; GMT ratio = 0.70 (95% CI: [0.61, 0.80]).


  • 15 REFERENCES

    1. Reitschel RL, Bernier R. Neomycin sensitivity and the MMR vaccine. JAMA 1981;245(6):571.
    2. Atkinson WL, Pickering LK, Schwartz B, Weniger BG, Iskander JK, Watson JC. General recommendations on immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP) and the American Academy of Family Physicians (AAFP). MMWR 2002;51(RR02):1-36.
    3. Rynn L, Cragan J, Correa A. Update on Overall Prevalence of Major Birth Defects-Atlanta, Georgia,1978-2005. CDC MMWR January 11, 2008/57(01);1-5.
    4. American College of Obstetricians and Gynecologists Frequently Asked Questions: Miscarriage and Molar Pregnancy; 2011.
    5. Coplan PM, Schmader K, Nikas A, Chan ISF, Choo P, Levin MJ, et al. Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: Adaptation of the brief pain inventory. J Pain 2004;5(6):344-56.

  • 16 HOW SUPPLIED/STORAGE AND HANDLING

    No. 4963-00 — ZOSTAVAX is supplied as follows: (1) a package of 1 single-dose vial of lyophilized vaccine, NDC 0006-4963-00 (package A); and (2) a separate package of 10 vials of diluent (package B).

    No. 4963-41 — ZOSTAVAX is supplied as follows: (1) a package of 10 single-dose vials of lyophilized vaccine, NDC 0006-4963-41 (package A); and (2) a separate package of 10 vials of diluent (package B).

    Storage

    To maintain potency, ZOSTAVAX must be stored frozen between -58°F and +5°F (-50°C and -15°C). Use of dry ice may subject ZOSTAVAX to temperatures colder than -58°F (-50°C).

    Before reconstitution, ZOSTAVAX SHOULD BE STORED FROZEN at a temperature between -58°F and +5°F (-50°C and -15°C) until it is reconstituted for injection. Any freezer, including frost-free, that has a separate sealed freezer door and reliably maintains a temperature between -58°F and +5°F (-50°C and -15°C) is acceptable for storing ZOSTAVAX.

    ZOSTAVAX may be stored and/or transported at refrigerator temperature between 36°F and 46°F (2°C to 8°C) for up to 72 continuous hours prior to reconstitution. Vaccine stored between 36°F and 46°F (2°C to 8°C) that is not used within 72 hours of removal from +5°F (-15°C) storage should be discarded. ZOSTAVAX should be reconstituted immediately upon removal from the freezer. The diluent should be stored separately at room temperature (68°F to 77°F, 20°C to 25°C), or in the refrigerator (36°F to 46°F, 2°C to 8°C).

    For further product information call 1-800-MERCK-90.

    Before reconstitution, protect from light.

    DO NOT FREEZE RECONSTITUTED VACCINE.


  • 17 PATIENT COUNSELING INFORMATION

    Advise the patient to read the FDA-approved patient labeling (Patient Information).

    • Question the patient about reactions to previous vaccines.
    • Provide a copy of the patient information (PPI) located at the end of this insert and discuss any questions or concerns.
    • Inform patient of the benefits and risks of ZOSTAVAX, including the potential risk of transmitting the vaccine virus to susceptible individuals, such as immunosuppressed or immunodeficient individuals or pregnant women who have not had chickenpox.
    • Instruct patient to report any adverse reactions or any symptoms of concern to their healthcare professional.

  • SPL UNCLASSIFIED SECTION


    Dist. by: Merck Sharp & Dohme Corp., a subsidiary of
    MERCK & CO., INC., Whitehouse Station, NJ 08889, USA

    For patent information: www.merck.com/product/patent/home.html

    Copyright © 2006-2017 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    All rights reserved.

    uspi-v211-i-fro-1709r022


  • PATIENT PACKAGE INSERT


    Patient Information about
    ZOSTAVAX® (pronounced "ZOS tah vax")
    Generic name: Zoster Vaccine Live

    You should read this summary of information about ZOSTAVAX before you are vaccinated. If you have any questions about ZOSTAVAX after reading this leaflet, you should ask your health care provider. This information does not take the place of talking about ZOSTAVAX with your doctor, nurse, or other health care provider. Only your health care provider can decide if ZOSTAVAX is right for you.

    What is ZOSTAVAX and how does it work?

    ZOSTAVAX is a vaccine that is used for adults 50 years of age or older to prevent shingles (also known as zoster).

    ZOSTAVAX contains a weakened chickenpox virus (varicella-zoster virus).

    ZOSTAVAX works by helping your immune system protect you from getting shingles.

    If you do get shingles even though you have been vaccinated, ZOSTAVAX may help prevent the nerve pain that can follow shingles in some people. ZOSTAVAX does not protect everyone, so some people who get the vaccine may still get shingles.

    ZOSTAVAX cannot be used to treat shingles, or the nerve pain that may follow shingles, once you have it.

    What do I need to know about shingles and the virus that causes it?

    Shingles is caused by the same virus that causes chickenpox. Once you have had chickenpox, the virus can stay in your nervous system for many years. For reasons that are not fully understood, the virus may become active again and give you shingles. Age and problems with the immune system may increase your chances of getting shingles.

    Shingles is a rash that is usually on one side of the body. The rash begins as a cluster of small red spots that often blister. The rash can be painful. Shingles rashes usually last up to 30 days and, for most people, the pain associated with the rash lessens as it heals.

    Who should not get ZOSTAVAX?

    You should not get ZOSTAVAX if you:

    • are allergic to any of its ingredients.
    • are allergic to gelatin or neomycin.
    • have a weakened immune system (for example, an immune deficiency, leukemia, lymphoma, or HIV/AIDS).
    • take medicines or receive treatment that might weaken your immune system (such as high doses of steroids by injection or by mouth).
    • are pregnant or plan to get pregnant.

    You should not get ZOSTAVAX to prevent chickenpox.

    Children should not get ZOSTAVAX.

    How is ZOSTAVAX given?

    ZOSTAVAX is given as a single dose by injection under the skin.

    What should I tell my health care provider before I get ZOSTAVAX?

    You should tell your health care provider if you:

    • have or have had any medical problems.
    • take or have taken any medicines, including non-prescription medicines, and dietary supplements.
    • have any allergies, including allergies to neomycin or gelatin.
    • had an allergic reaction to another vaccine.
    • are pregnant or plan to become pregnant.
    • are breast-feeding.

    Tell your health care provider if you expect to be in close contact (including household contact) with newborn infants, someone who may be pregnant and has not had chickenpox or been vaccinated against chickenpox, or someone who has problems with their immune system. Your health care provider can tell you what situations you may need to avoid.

    Can I get ZOSTAVAX with other vaccines?

    ZOSTAVAX can be given at the same time as inactivated flu vaccine.

    Talk to your health care provider if you plan to get ZOSTAVAX at the same time as PNEUMOVAX® 23 because it may be better to get these vaccines at least 4 weeks apart.

    What are the possible side effects of ZOSTAVAX?

    The most common side effects that people in the clinical studies reported after receiving the vaccine include:

    • redness, pain, itching, swelling, hard lump, warmth, or bruising where the shot was given.
    • headache

    The following additional side effects have been reported with ZOSTAVAX:

    • allergic reactions, which may be serious and may include difficulty in breathing or swallowing. If you have an allergic reaction, call your doctor right away.
    • chickenpox
    • fever
    • hives at the injection site
    • joint pain
    • muscle pain
    • nausea
    • rash
    • rash at the injection site
    • shingles
    • swollen glands near the injection site (that may last a few days to a few weeks)

    Tell your healthcare provider if you have any new or unusual symptoms after you receive ZOSTAVAX. For a complete list of side effects, ask your health care provider.

    Report the following to your doctor or your child's doctor:

    • any adverse reactions following vaccination
    • exposure to ZOSTAVAX during pregnancy
    • exposure to ZOSTAVAX during the 3 months before getting pregnant.
       
      You may also report these events to Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., at 1-877-888-4231, or directly to the Vaccine Adverse Event Reporting System (VAERS). The VAERS toll free number is 1-800-822-7967 or report online to www.vaers.hhs.gov.

    What are the ingredients of ZOSTAVAX?

    Active Ingredient: a weakened form of the varicella-zoster virus.

    Inactive Ingredients: sucrose, hydrolyzed porcine gelatin, sodium chloride, monosodium L-glutamate, sodium phosphate dibasic, potassium phosphate monobasic, potassium chloride.

    This leaflet summarizes important information about ZOSTAVAX. If you would like more information, talk to your health care provider or visit the website at www.ZOSTAVAX.com or call 1-800-622-4477.


  • SPL UNCLASSIFIED SECTION

    Dist. by: Merck Sharp & Dohme Corp., a subsidiary of
    MERCK & CO., INC., Whitehouse Station, NJ 08889, USA

    For patent information: www.merck.com/product/patent/home.html

    Copyright © 2006-2017 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    All rights reserved.

    Revised: 09/2017

    usppi-v211-i-fro-1709r018


  • PRINCIPAL DISPLAY PANEL - 0.65 mL Vial Carton

    A

    NDC 0006-4963-00
    1 Single-dose Vial (0.65 mL)

    Zoster Vaccine Live
    ZOSTAVAX®

    STORE FROZEN

    Oka/Merck strain. Human
    diploid cell (MRC-5) culture
    origin. Each 0.65-mL
    dose contains a
    minimum of 19,400 PFU
    (plaque-forming units).

    Contains no preservative.
    Contains trace quantities
    of neomycin.

    Rx only

    PRINCIPAL DISPLAY PANEL - 0.65 mL Vial Carton

  • PRINCIPAL DISPLAY PANEL - 0.7 mL Vial Carton

    NDC 0006-4309-00

    10 Single-Dose
    0.7-mL Vials

    STERILE DILUENT

    FOR MERCK SHARP & DOHME CORP.
    LIVE VIRUS VACCINES
    (Sterile Water)

    Rx only
    B

    CONTAINS NO PRESERVATIVE

    This carton contains 10 diluent-containing vials. Use one diluent vial
    for reconstitution of one single-dose vial of live virus vaccine.

    PRINCIPAL DISPLAY PANEL - 0.7 mL Vial Carton

  • INGREDIENTS AND APPEARANCE
    ZOSTAVAX 
    zoster vaccine live injection, powder, lyophilized, for suspension
    Product Information
    Product Type VACCINE Item Code (Source) NDC:0006-4963
    Route of Administration SUBCUTANEOUS
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    VARICELLA-ZOSTER VIRUS STRAIN OKA/MERCK LIVE ANTIGEN (UNII: GPV39ZGD8C) (VARICELLA-ZOSTER VIRUS STRAIN OKA/MERCK LIVE ANTIGEN - UNII:GPV39ZGD8C) VARICELLA-ZOSTER VIRUS STRAIN OKA/MERCK LIVE ANTIGEN 19400 [PFU]  in 0.65 mL
    Inactive Ingredients
    Ingredient Name Strength
    ALBUMIN BOVINE (UNII: 27432CM55Q)  
    GELATIN, UNSPECIFIED (UNII: 2G86QN327L) 15.58 mg  in 0.65 mL
    MONOSODIUM GLUTAMATE (UNII: W81N5U6R6U) 0.62 mg  in 0.65 mL
    POTASSIUM CHLORIDE (UNII: 660YQ98I10) 0.1 mg  in 0.65 mL
    POTASSIUM PHOSPHATE, MONOBASIC (UNII: 4J9FJ0HL51) 0.1 mg  in 0.65 mL
    SODIUM CHLORIDE (UNII: 451W47IQ8X) 3.99 mg  in 0.65 mL
    SODIUM PHOSPHATE, DIBASIC, UNSPECIFIED FORM (UNII: GR686LBA74) 0.57 mg  in 0.65 mL
    SUCROSE (UNII: C151H8M554) 31.16 mg  in 0.65 mL
    NEOMYCIN (UNII: I16QD7X297)  
    Product Characteristics
    Color WHITE, YELLOW (off-white to pale yellow) Score     
    Shape Size
    Flavor Imprint Code
    Contains     
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:0006-4963-00 1 in 1 CARTON
    1 NDC:0006-4963-01 0.65 mL in 1 VIAL, SINGLE-DOSE; Type 0: Not a Combination Product
    2 NDC:0006-4963-41 10 in 1 CARTON
    2 NDC:0006-4963-01 0.65 mL in 1 VIAL, SINGLE-DOSE; Type 0: Not a Combination Product
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    BLA BLA125123 05/25/2006
    STERILE DILUENT 
    sterile water injection
    Product Information
    Product Type VACCINE Item Code (Source) NDC:0006-4309
    Route of Administration SUBCUTANEOUS
    Inactive Ingredients
    Ingredient Name Strength
    WATER (UNII: 059QF0KO0R) 0.7 mL  in 0.7 mL
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:0006-4309-00 10 in 1 CARTON
    1 NDC:0006-4309-01 0.7 mL in 1 VIAL, SINGLE-DOSE; Type 0: Not a Combination Product
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    BLA BLA125123 05/25/2006
    Labeler - Merck Sharp & Dohme Corp. (001317601)